Santhosh Nathan1, Zahra Goodarzi1, Nathalie Jette1, Clare Gallagher1, Jayna Holroyd-Leduc2. 1. From the Cumming School of Medicine (S.N.), Departments of Medicine (Z.G., J.H.-L.), Community Health Sciences (N.J., J.H.-L.), and Clinical Neurosciences (N.J., C.G.), Hotchkiss Brain Institute (N.J., C.G., J.H.-L.), and O'Brien Institute for Public Health (N.J., J.H.-L.), University of Calgary, Canada. 2. From the Cumming School of Medicine (S.N.), Departments of Medicine (Z.G., J.H.-L.), Community Health Sciences (N.J., J.H.-L.), and Clinical Neurosciences (N.J., C.G.), Hotchkiss Brain Institute (N.J., C.G., J.H.-L.), and O'Brien Institute for Public Health (N.J., J.H.-L.), University of Calgary, Canada. jayna.holroyd-leduc@ahs.ca.
Abstract
OBJECTIVE: To address whether to restart older patients on anticoagulants or antiplatelet agents in the setting of a chronic subdural hematoma (cSDH). METHODS: This is an update of a previous review (searched until July 2012). Medline, EMBASE, ISI Web of Knowledge, Google Scholar, PLOS, and the Cochrane Register for Systematic Reviews databases were searched from January 2012 to December 2016. Studies included older adults (those over 65 years) experiencing traumatic subdural hematoma or cSDH who were on anticoagulation or antiplatelet agents. RESULTS: Seven studies were included (mean age 72 years). Four out of 7 studies provided combined data on anticoagulants or antiplatelet use. Only one study found anticoagulant or antiplatelet agent use to be a significant factor for cSDH rebleeding. Two studies considered anticoagulant use only and both reported similar increased odds of rebleeding (odds ratio [OR] 1.75, 95% confidence interval [CI] 0.18-16.86; OR 2.7 95% CI 1.42-6.96). Antiplatelets were not found to be associated with rebleeding. Ideal timing to resume anticoagulants or antiplatelets was unclear. CONCLUSIONS: Anticoagulant medication was associated with increased rebleeding risk in older adults with cSDH. However, antiplatelet medication was not associated with increased risk of rebleeding.
OBJECTIVE: To address whether to restart older patients on anticoagulants or antiplatelet agents in the setting of a chronic subdural hematoma (cSDH). METHODS: This is an update of a previous review (searched until July 2012). Medline, EMBASE, ISI Web of Knowledge, Google Scholar, PLOS, and the Cochrane Register for Systematic Reviews databases were searched from January 2012 to December 2016. Studies included older adults (those over 65 years) experiencing traumatic subdural hematoma or cSDH who were on anticoagulation or antiplatelet agents. RESULTS: Seven studies were included (mean age 72 years). Four out of 7 studies provided combined data on anticoagulants or antiplatelet use. Only one study found anticoagulant or antiplatelet agent use to be a significant factor for cSDH rebleeding. Two studies considered anticoagulant use only and both reported similar increased odds of rebleeding (odds ratio [OR] 1.75, 95% confidence interval [CI] 0.18-16.86; OR 2.7 95% CI 1.42-6.96). Antiplatelets were not found to be associated with rebleeding. Ideal timing to resume anticoagulants or antiplatelets was unclear. CONCLUSIONS: Anticoagulant medication was associated with increased rebleeding risk in older adults with cSDH. However, antiplatelet medication was not associated with increased risk of rebleeding.
Authors: Hussam A Hamou; Hans Clusmann; Jörg B Schulz; Martin Wiesmann; Ertunc Altiok; Anke Höllig Journal: Dtsch Arztebl Int Date: 2022-03-25 Impact factor: 8.251
Authors: Minna Rauhala; Pauli Helén; Karri Seppä; Heini Huhtala; Grant L Iverson; Tero Niskakangas; Juha Öhman; Teemu M Luoto Journal: Acta Neurochir (Wien) Date: 2020-03-07 Impact factor: 2.216